GEMINI 3CD · Induction and maintenance
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed
Sands BE, et al.
Gastroenterology 2014 · PMID 24859203 (PubMed, opens in a new tab) · doi 10.1053/j.gastro.2014.05.008 (full paper, opens in a new tab)
| Endpoint | Vedolizumab | Placebo | Difference |
|---|---|---|---|
| Clinical remission, Week 6 (primary endpoint) | 15.2% | 12.1% | P=0.433 (not significant) |
| Clinical remission, Week 10 | 26.6% | 12.1% | Relative risk 2.2 (95% CI 1.3–3.6); nominal P=0.001 |
| CDAI-100 response, Week 6 | 39.2% | 22.3% | Relative risk 1.8 (95% CI 1.2–2.5); nominal P=0.001 |
Remission separated from placebo only by week 10, after the third infusion.
Source: Sands 2014, abstract. Week-10 remission and week-6 response were secondary analyses with nominal P values.
Structured abstract
BackgroundPatients with Crohn's disease who had failed TNF antagonists needed new options, and GEMINI 2 suggested vedolizumab acts slowly; GEMINI 3 tested three-dose induction in this group.
MethodsPhase 3, randomised, double-blind, placebo-controlled induction trial; outcomes to week 10. 416 patients. Primary endpoint: Clinical remission (CDAI ≤150) at week 6 in patients with previous TNF-antagonist failure.
ResultsPrimary result. 15.2% vs 12.1%; P=0.433 (not significant)
Take-homeAfter anti-TNF failure in Crohn's disease, vedolizumab missed its week-6 remission endpoint but showed benefit by week 10, so judge response later than with faster-acting drugs.
| Patients | 416 |
|---|---|
| Population | Moderately to severely active Crohn's disease (CDAI 220–400). Primary analysis: 315 patients with previous failure (inadequate response, loss of response or intolerance) of at least one TNF antagonist. The overall population also included 101 patients naive to TNF antagonists. |
| Comparison | Vedolizumab 300 mg IV vs placebo at weeks 0, 2 and 6 |
| Drugs | vedolizumab |
| Classes | Anti-integrin |
| Published | Sands BE, et al. Gastroenterology 2014;147:618–27. |
Key points
- By week 10, remission was higher with vedolizumab in the TNF-antagonist-failure group: 26.6% vs 12.1% (nominal P=0.001; relative risk 2.2, 95% CI 1.3–3.6).
- CDAI-100 response at week 6 was higher with vedolizumab: 39.2% vs 22.3% (nominal P=0.001; relative risk 1.8, 95% CI 1.2–2.5).
- Unlike GEMINI 2, induction included a third infusion at week 6.
- Adverse events were similar across groups.
Limitations
- The week-10 results were secondary endpoints with nominal P values.
- Induction only (10 weeks); no maintenance phase.
- Symptom-based endpoints (CDAI) without endoscopy.
Commentary
Why it matters. GEMINI 3 was designed for the hardest group: patients whose anti-TNF therapy had failed. It confirmed the lesson of GEMINI 2: vedolizumab works in Crohn’s disease, but slowly. The difference from placebo was small at week 6 and clearer at week 10.
In practice. Induction is three infusions (weeks 0, 2 and 6), and response should not be judged at week 6. The Canadian product monograph (Takeda Canada, revised November 2023) advises stopping vedolizumab in Crohn’s disease if there is no evidence of benefit by week 14. Patients with severe symptoms may need a bridge, often a corticosteroid, while waiting for the effect.
Later evidence. After anti-TNF failure, IL-23 p19 inhibitors now have head-to-head data: risankizumab beat ustekinumab for endoscopic remission in SEQUENCE. Subcutaneous vedolizumab maintenance for Crohn’s disease was tested in VISIBLE 2.
Journal club
Design
Phase 3, randomised, double-blind, placebo-controlled induction trial; outcomes to week 10. 416 patients.
Primary result. 15.2% vs 12.1%; P=0.433 (not significant)
Validity and applicability
- The week-10 results were secondary endpoints with nominal P values.
- Induction only (10 weeks); no maintenance phase.
- Symptom-based endpoints (CDAI) without endoscopy.
Where it sits now
After anti-TNF failure in Crohn's disease, vedolizumab missed its week-6 remission endpoint but showed benefit by week 10, so judge response later than with faster-acting drugs.
- GEMINI 2 (2013): Vedolizumab works in Crohn's disease but slowly: modest at week 6, clearer by week 10 and in maintenance, so it suits patients who can wait for the effect.
- SEQUENCE (2024): After anti-TNF failure, risankizumab beats ustekinumab for endoscopic remission, so an IL-23 p19 inhibitor is the stronger second-line choice of the two.
- VISIBLE 2 (2022): After two IV doses, vedolizumab 108 mg SC every 2 weeks maintains remission in Crohn's disease better than placebo, so patients can switch to home injections.
- RELIEVE UCCD (CD) (2026): Duvakitug, an anti-TL1A antibody, gave a dose-related endoscopic response signal in Crohn's disease in phase 2b; phase 3 trials will decide whether TL1A becomes a new Crohn's disease target.
Questions for discussion
- The primary endpoint failed, but week-10 results looked positive. How much should nominal P values on secondary endpoints change practice?
- Placebo remission was 12.1% at both week 6 and week 10. What does the stable placebo rate tell you about the week-10 vedolizumab result?
- When would you judge vedolizumab response in Crohn's disease after anti-TNF failure, and what would you do while waiting?